DLL3 and neuroendocrine carcinoma: The DLL3-targeting T Cell engager BI 764532 is currently being evaluated in the DAREONTM-5 open-label, multicenter phase II dose-selection trial, in patients with relapsed/refractory neuroendocrine carcinomas (NCT05882058).